Health Condition 1: L400- Psoriasis vulgaris Health Condition 2: L400- Psoriasis vulgaris
Conditions
Interventions
Intervention1: Tofacitinib: Patient alloted in this arm will be given T.tofacitinib 5mg BD daily for 6 months
Control Intervention1: Methotrexate: Patient allotted in this arm will be given T. Methotr
Sponsors
None
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients of either sex and age 18-70 years. 2. PASI >12 or BSA >10%
Exclusion criteria
Exclusion criteria: 1. Age less than 18 or more than 70 years 2. Individuals with severe anaemia, leukopenia(lymphocytes 3. Individuals with heavy alcohol consumption ( >14 units/week) or heavy smokers. 4. Individuals on concomitant medications such as high dose vitamin D, oral/topical steroids, PUVA, Acitretin, Dapsone, Sulfamethoxazole, Trimethoprim 5. Pregnant and lactating women 6. Patient having pre-existing uncontrolled Diabetes mallitus , Hypertension 7. Patients who have taken any immunosuppressant drugs, homeopathic/herbal medications in last 4 weeks. 8. Patients with malignancies/ history of malignancy. 9. Patients with risk/history of thromboembolism, cardiovascular accidents. 10. Patients with active infection, active/latent tuberculosis. 11. Patients found to have abnormal laboratory parameters that would increase the risk of adverse effect
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| improvement in PASI by 75% from baseline at 12 weekTimepoint: improvement in PASI by 75% from baseline at 12 week | — |
Secondary
| Measure | Time frame |
|---|---|
| Improvement in PASI by 100% from baseline Physicians global assessment Dermatological Quality of life Index Safety analysisTimepoint: At 24 week | — |
Countries
India
Contacts
Public ContactDrJahnvi Patel
GCS Medical College, Hospital and Research Centre
Outcome results
None listed